Analyst Reco. Orexo AB

Equities

Delayed Nasdaq Stockholm Other stock markets 11:59:53 08/05/2024 BST			5-day change	1st Jan Change
19.2 ^SEK	0.00%		+11.63%	+24.19%

04-17	Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	MT
04-17	Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	CI

Orexo's Opioid Use Disorder Drug Study Shows Unexpectedly High Treatment Response Rates	11/10/23	MT
Orexo AB Issues Senior Unsecured Callable Floating Rate Bonds in Amount of SEK 500 Million	04/02/21	CI

No results for this search